Article Text

Download PDFPDF
Initial results with recombinant interferon alfa-2b in patients with chronic hepatitis C: the United States experience.
  1. G L Davis
  1. Section of Hepatobiliary Diseases, University of Florida College of Medicine, Gainesville 32610-0214.


    Early experience with recombinant interferon alfa-2b in chronic hepatitis C (HCV) has shown that normalisation of serum alanine aminotransferase activities and reduction in hepatic inflammation can be achieved in about 40% of patients. This occurs with loss of viral replication as measured by polymerase chain reaction for HCV-RNA. Further studies are needed to identify patients most likely to respond to treatment and to investigate the issues of non-response and relapse when treatment is stopped. Alternative interferon treatment regimens, as well as other drugs and combinations of agents, need to be investigated.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.